ACHFF Arch Biopartners Inc.

Arch Biopartners, Inc. is a portfolio based biotechnology company. It is focused on the development of innovative technologies that have the potential to make a significant medical or commercial impact. The company has five technology platforms which includes: AB569, MetaBlok, Arch Inflammation, Borg:Peptide-Solid Surface Interface and MetaMx. Arch Biopartners was founded by Richard Gabriel Muruve and Daniel Muruve on March 4, 1983 and is headquartered in Toronto, Canada.

This security is traded over-the-counter, or OTC. We don't always have accurate pricing data on OTC stocks.

$2.83    OTCQB
As of 01/21/2022     OTCMarkets


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  Canada
Country of incorporation:  
IPO date:  04/24/2002
Outstanding shares:  61,962,302
Average volume:  15,237
Market cap:   $176,282,749
Current dividend yield:  0.00%
Sedol:      
Valuation   (See tab for details)
PE ratio:   -36.11
PB ratio:   -707.00
PS ratio:   0.00
Return on equity:   113.81%
Net income %:   -19,523.59%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy